Providing hope - Improving lives
The Translational Therapeutics Lab seeks to translate our understanding of the brain bases of emotion and behavior to develop rapid-acting treatments for mental illness. We partner with collaborators at multiple points along the drug discovery and development pathway to discover new treatments across the lifespan.
Our interdisciplinary approach involves identifying promising compounds and designing clinical trials that simultaneously provide information about mechanism and efficacy. We utilize multiple modalities (fMRI, EEG, MRS) to understand where and when compounds are targeting the brain at multiple levels including molecules, circuits, networks, and behaviors to produce rapid relief of symptoms.
We are committed to educating the public about mental illness and clinical research.
Congratulations Dr. Omer Linkovski for the IOCDF 2017 Research Poster Travel Award!
Poster Title: "Can Priming Inhibitory Control Affect Resolution of Uncertainty?"
The 24th Annual OCD Conference will be held on July 7-9, 2017 in San Francisco.
Webinar: ‘Towards Rapid-Acting Treatments for OCD’
Brain and Behavior Research Foundation. (2017, June 13).
Podcast: ‘Special K’ A Potential Treatment for OCD?
Scope. (2017, June 5). Stanford Medicine.
Early Test Shows: Experimental Drug May Have Potential to Relieve OCD Symptoms Quickly and with Few Side Effect
eNews. (2017, May 25). Brain & Behavior Research Foundation.
Researcher Investigates Hallucinogen as Potential OCD Treatment
White, T. (2017, May 19). Stanford Medicine.